Page 136 - 2020年2月第31卷第3期
P. 136

使用。目前,国外SCIg的临床应用已经日趋成熟,SCIg                             无反应诱导[J].国外医学:输血及血液学分册,1999(1):
        被广泛应用于原发性免疫缺陷病患者、自身免疫性疾病                                 64-65.
        患者、炎症患者、感染患者和肿瘤患者的治疗,并表现出                           [12]  EL-SAYED ZA,ABRAMOVA I,ALDAVE JC,et al. X-
        一系列 IVIg 所不具备的优点,如可在家使用、可自我管                             linked agammaglobulinemia(XLA):phenotype,diagno-
        理、副作用低、可更加稳定地维持生理水平的 IgG 浓度                              sis,and therapeutic challenges around the world[J]. World
                                                                 Allergy Organ J,2019.DOI:10.1016/j.waoju.2019.100018.
        等。但我国尚无相关 SCIg 的报道,也没有 SCIg 的研发
                                                            [13]  JOLLES S,ORANGE JS,GARDULF A,et al. Current
        和生产。建议我国相关科研人员在对 IVIg 进行研究的
                                                                 treatment options with immunoglobulin G for the individu-
        同时,也可将SCIg纳入研究范围;同时,我国血液制品生
                                                                 alization of care in patients with primary immunodeficien-
        产企业在生产 IVIg 等血液制品时,也可将 SCIg 纳入研
                                                                 cy disease[J]. Clin Exp Immunol,2015,179(2):146-160.
        发范围,以满足未来更广泛的免疫球蛋白治疗需求。
                                                            [14]  OCHS HD,GUPTA S,KIESSLING P,et al. Safety and ef-
        SCIg的研发和生产可丰富免疫球蛋白药物种类,为免疫                               ficacy of self-administered subcutaneous immunoglobulin
        球蛋白替代治疗提供更多药物选择,有利于个性化治疗                                 in patients with primary immunodeficiency diseases[J]. J
        方案的制订、临床疗效的提高和血液资源的合理利用。                                 Clin Immunol,2006,26(3):265-273.
        参考文献                                                [15]  NICOLAY U,KIESSLING P,BERGER M,et al. Health-
        [ 1 ]  SPATH PJ,SCHNEIDER C,VON GUNTEN S. Clinical       related quality of life and treatment satisfaction in North
             use and therapeutic potential of IVIG/SCIG,plasma-de-  American patients with primary immunedeficiency diseas-
             rived IgA or IgM,and other alternative immunoglobulin  es receiving subcutaneous IgG self-infusions at home[J]. J
             preparations[J]. Arch Immunol Ther Exp:Warsz,2017,65  Clin Immunol,2006,26(1):65-72.
             (3):215-231.                                   [16]  BOOKBINDER LH,HOFER A,HALLER MF,et al. A re-
        [ 2 ]  PEREZ EE,ORANGE JS,BONILLA F,et al. Update on     combinant human enzyme for enhanced interstitial trans-
             the use of immunoglobulin in human disease:a review of  port of therapeutics[J]. J Control Release,2006,114(2):
             evidence[J]. J Allergy Clin Immunol,2017.DOI:10.1016/j.  230-241.
             jaci.2016.09.023.                              [17]  SUPERSAXO A,HEIN WR,STEFFEN H. Effect of mo-
        [ 3 ]  王君君,郑显兰.免疫球蛋白在原发性抗体缺陷病中的应                         lecular weight on the lymphatic absorption of water-solu-
             用及护理进展[J].护理学杂志,2015,30(17):102-105.                ble compounds following subcutaneous administration[J].
        [ 4 ]  ESPANOL T,PREVOT J,DRABWELL J,et al. Improv-      Pharm Res,1990,7(2):167-169.
             ing current immunoglobulin therapy for patients with pri-  [18]  KANG DW,JADIN L,NEKOROSKI T,et al. Recombi-
             mary immunodeficiency:quality of life and views on treat-  nant human hyaluronidase PH20 (rHuPH20) facilitates
             ment[J]. Patient Prefer Adherence,2014.DOI:10.2147/  subcutaneous infusions of large volumes of immunoglobu-
             PPA.S60771.                                         lin in a swine model[J]. Drug Deliv Transl Re,2012,2
        [ 5 ]  SHAPIRO RS. Why I use subcutaneous immunoglobulin  (4):254-264.
             (SCIg)[J]. J Clin Immunol,2013,33(2):95-98.    [19]  JOLLES S. Hyaluronidase facilitated subcutaneous immu-
        [ 6 ]  BASTIN K,BIELBY L,DALY J. Helping patients in Vic-  noglobulin in primary immunodeficiency[J]. Immunotar-
             toria access subcutaneous immunoglobulin[J]. Intern Med  gets Ther,2013.DOI:10.2147/ITT.S31136.
             J,2018.DOI:10.1111/imj.14077.                  [20]  WIESIK-SZEWCZYK E,JAHNZ-RÓZYK K. A case re-
        [ 7 ]  DUNN R,DUNNE G,SULLIVAN A,et al. Development      port of pregnancy in a patient with common variable im-
             of new ASCIA subcutaneous immunoglobulin(SCIg)re-   munodeficiency emphasizing the need for personalized
             sources[J]. Intern Med J,2018.DOI:10.1111/imj.14077.  immunoglobulin replacement[J]. Medicine:Baltimore,
        [ 8 ]  尹婉宜,刘清池,贾晓辉,等.泼尼松联合静注人免疫球蛋                        2018.DOI:10.1097/MD.0000000000012804.
             白(pH4)治疗特发性血小板减少性紫癜的临床观察[J].                   [21]  BONDT A,WUHRER M,KUIJPER TM,et al. Fab glyco-
             中国药房,2016,27(27):3771-3774.                         sylation of immunoglobulin G does not associate with im-
        [ 9 ]  裴保香,吴润东,董圣惠.静脉滴注人免疫球蛋白辅助治                         provement of rheumatoid arthritis during pregnancy[J]. Ar-
             疗重症肺炎的疗效观察[J].中国药房,2010,21(36):                     thritis Res Ther,2016.DOI:10.1186/s13075-016-1172-1.
             3409-3411.                                     [22]  AHMED AA,GIDDENS J,PINCETIC A,et al. Structural
        [10]  彭霞,喻文.皮下注射免疫球蛋白在重症肌无力恶化治疗                          characterization of anti-inflammatory immunoglobulin G
             中的作用:一项前瞻性开放性临床试验[J].中华危重病                          Fc proteins[J]. J Mol Biol,2014,426(18):3166-3179.
             急救医学,2018,30(4):364.                           [23]  TJON AS,VAN GENT R,GEIJTENBEEK TB,et al. Dif-
        [11]  孔维权.皮下注射免疫球蛋白治疗IgA缺乏病人的抗IgA                        ferences in anti-inflammatory actions of intravenous im-


        ·382  ·  China Pharmacy 2020 Vol. 31 No. 3                                   中国药房    2020年第31卷第3期
   131   132   133   134   135   136   137   138   139   140   141